Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis

Manuel M. Garrido, Ruy M. Ribeiro, Kimberly Krueger, Luis C. Pinheiro, Joao T. Guimaraes, Stefan Holdenrieder

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: Evasion from cell death occurs in prostate cancer (PCa). We verified whether serum levels of cell death markers can have diagnostic value in PCa. Patients and Methods: A total of 233 men scheduled for prostate biopsy [prostate specific antigen (PSA) level: 2-10 ng/ml] were enrolled. Serum nucleosomes, nucleosomes containing the H3 histone (H3), high mobility group box 1 (HMGB1), and soluble receptor for advanced glycation end products (sRAGE) were analyzed by enzyme immunoassays. Results: There were no differences (p>0.05) in nucleosomes, H3, and sRAGE levels between patients with and without PCa or clinically significant PCa (csPCa). HMGB1 had lower levels in PCa patients (p=0.023) and was a predictor of PCa (p=0.047), but not of csPCa (p=0.180). Conclusion: In patients with critical PSA levels between 2-10 ng/ml, HMGB1 had some diagnostic value for overall PCa detection, but it was not predictive of csPCa. Nucleosomes, H3 and sRAGE did not discriminate between PCa or csPCa and controls.

Original languageEnglish
Pages (from-to)2207-2212
JournalIn Vivo
Volume35
Issue number4
DOIs
Publication statusPublished - 2021

Keywords

  • Prostate cancer
  • circulating nucleosomes
  • cell death detection ELISA
  • immunogenic cell death markers
  • sRAGE
  • HMGB1

Cite this